Caisse de depot et placement du Quebec Invests $105.28 Million in Thermo Fisher Scientific Inc. $TMO

Caisse de depot et placement du Quebec acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 209,989 shares of the medical research company’s stock, valued at approximately $105,280,000. Caisse de depot et placement du Quebec owned approximately 0.06% of Thermo Fisher Scientific as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the business. High Note Wealth LLC raised its stake in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares in the last quarter. Swiss RE Ltd. purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth about $28,000. Kilter Group LLC acquired a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $25,000. Birchwood Financial Partners Inc. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $29,000. Finally, Legacy Wealth Managment LLC ID raised its holdings in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Piper Sandler lifted their price objective on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research report on Monday, July 27th. Wolfe Research started coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price on the stock. Barclays raised their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Finally, Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 73,768 shares of company stock valued at $44,122,820 over the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $634.48 on Thursday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $647.00. The stock has a market cap of $234.60 billion, a PE ratio of 34.13, a price-to-earnings-growth ratio of 2.56 and a beta of 0.85. The firm has a fifty day moving average price of $552.22 and a 200 day moving average price of $510.70.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.